$31.99
2.02% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$32.65
-1.46 4.28% 1M
+3.65 12.59% 6M
+3.89 13.53% YTD
+5.88 21.96% 1Y
+4.40 15.58% 3Y
+18.85 136.67% 5Y
-26.49 44.79% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.12 0.37%
ISIN
IE00B56GVS15
Symbol
ALKS
Sector
Industry

Key metrics

Market capitalization $5.31b
Enterprise Value $4.63b
P/E (TTM) P/E ratio 14.98
EV/FCF (TTM) EV/FCF 11.42
EV/Sales (TTM) EV/Sales 2.97
P/S ratio (TTM) P/S ratio 3.41
P/B ratio (TTM) P/B ratio 3.61
Revenue growth (TTM) Revenue growth -6.36%
Revenue (TTM) Revenue $1.56b
EBIT (operating result TTM) EBIT $420.64m
Free Cash Flow (TTM) Free Cash Flow $405.64m
Cash position $751.67m
EPS (TTM) EPS $2.18
P/E forward 28.68
P/S forward 3.80
EV/Sales forward 3.31
Short interest 11.86%
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Alkermes Plc forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a Alkermes Plc forecast:

Buy
60%
Hold
40%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,558 1,558
6% 6%
100%
- Direct Costs 252 252
15% 15%
16%
1,306 1,306
4% 4%
84%
- Selling and Administrative Expenses 617 617
4% 4%
40%
- Research and Development Expense 240 240
33% 33%
15%
449 449
23% 23%
29%
- Depreciation and Amortization 29 29
62% 62%
2%
EBIT (Operating Income) EBIT 421 421
45% 45%
27%
Net Profit 367 367
3% 3%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Neutral
PRNewsWire
about 21 hours ago
DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m.
Neutral
PRNewsWire
2 days ago
DUBLIN , April 1, 2025 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for n...
Neutral
PRNewsWire
7 days ago
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life – – 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect – DUBLIN , March 27,...
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 1,800
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today